Oct 7 (Reuters) - CAMP4 Therapeutics, a

biopharmaceutical company backed by healthcare giant Kaiser

Permanente, said on Monday it was targeting a valuation of up to

$283 million in its initial public offering in the United

States.

The company will join a pack of biotech firms that have

listed their shares recently as a long-awaited policy-easing

cycle begins. Startups are also looking to get ahead of the

potential uncertainty from the U.S. presidential election next

month.

CAMP4 is seeking proceeds of up to $80 million through a

sale of 5 million shares priced between $14 and $16 each.

The Cambridge, Massachusetts-based company is developing

therapies to treat a broad range of genetic diseases. Its lead

product candidate, CMP-CPS-001, for treating the most prevalent

urea cycle disorders is being evaluated in an early-stage

clinical trial.

CAMP4 is led by Josh Mandel-Brehm, who previously worked at

Biogen and Sanofi.

It will seek a listing on Nasdaq under the symbol "CAMP".

J.P. Morgan, Leerink Partners, Piper Sandler and William Blair

are the underwriters for the IPO.